Press Releases

<<  Back

  View printer-friendly version

Allergen Research Corporation Renamed Aimmune Therapeutics

BRISBANE, Calif., May 27, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced that the company has changed its name from Allergen Research Corporation (ARC) to Aimmune Therapeutics.

As Aimmune Therapeutics, the company has introduced a new corporate identity and logo that honors its heritage while reflecting its evolution and steadfast mission: to address the urgent and growing unmet need to protect people with food allergies from the dangers of accidental exposure to their allergens. For more information, please see Aimmune’s new website at www.aimmune.com.

About Food Allergies

Food allergies are a significant and growing health problem in the United States, Europe and throughout the developed world. It is estimated that more than 30 million people in the United States and Europe have a food allergy. Specifically, the prevalence of peanut allergy in children in the United States is estimated to have increased at a constant annual growth rate of 10 percent between 1997 and 2008, and experts believe it has continued to rise. For people living with food allergies, certain foods can cause severe allergic reactions, including potentially life-threatening anaphylaxis. There is no cure for food allergies. Currently, food-allergic patients manage their condition by strict allergen avoidance and carrying epinephrine auto-injectors for use in case of accidental exposure. Thus, in addition to the unmet medical need, food allergies can impose a significant quality of life burden. For more information, please see www.foodallergy.org and www.niaid.nih.gov/topics/foodallergy.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research Corporation (ARC), is a clinical-stage biopharmaceutical company developing treatments for peanut and other food allergies. Aimmune Therapeutics’ characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), combines proprietary product candidates with gradual, controlled up-dosing protocols to obtain meaningful desensitization to food allergens. Aimmune Therapeutics recently completed a Phase 2 study of its lead product, AR101, a standardized, complex mixture of naturally occurring proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies. Aimmune Therapeutics is also developing products for other common food allergies for use with the CODIT system. For more information, please see www.aimmune.com.